Institution
University of Düsseldorf
Education•Düsseldorf, Germany•
About: University of Düsseldorf is a education organization based out in Düsseldorf, Germany. It is known for research contribution in the topics: Population & Diabetes mellitus. The organization has 25225 authors who have published 49155 publications receiving 1946434 citations.
Topics: Population, Diabetes mellitus, Transplantation, Gene, Medicine
Papers published on a yearly basis
Papers
More filters
University of Augsburg1, Utrecht University2, National Institutes of Health3, Imperial College London4, University of Manchester5, National and Kapodistrian University of Athens6, National Technical University of Athens7, Umeå University8, University of Düsseldorf9, University of Crete10, University of Basel11, Swiss Tropical and Public Health Institute12, Norwegian Institute of Public Health13, University of Duisburg-Essen14, ARPA-E15, University of Washington16, University of Pavia17
TL;DR: The ESCAPE study as mentioned in this paper investigated the long-term effects of exposure to air pollution on human health in Europe and found significant contrasts in annual average NO2 and NOx concentrations between and especially within 36 study areas across Europe.
301 citations
Memorial Sloan Kettering Cancer Center1, Kyoto University2, Harvard University3, University of Pavia4, Leeds Teaching Hospitals NHS Trust5, University of Göttingen6, Karolinska Institutet7, University of Düsseldorf8, Paris Descartes University9, University of Bologna10, Hannover Medical School11, Federal University of Ceará12, University of Florence13, Democritus University of Thrace14, University of Oxford15, Gifu University16, Chulalongkorn University17, University of Rochester18, Vanderbilt University19, Carlos III Health Institute20, University of Paris21, University of York22, Leipzig University23, Medical University of Vienna24, University of Tsukuba25, Nagasaki University26, University of Rome Tor Vergata27, Chang Gung University28, Radboud University Nijmegen29, Howard Hughes Medical Institute30, University of California, San Diego31, Stanford University32
TL;DR: Clinical sequencing across a large prospective cohort of patients with myelodysplasic syndrome uncovers distinct associations between the mono- and biallelic states of TP53 and clinical presentation.
Abstract: Tumor protein p53 (TP53) is the most frequently mutated gene in cancer1,2. In patients with myelodysplastic syndromes (MDS), TP53 mutations are associated with high-risk disease3,4, rapid transformation to acute myeloid leukemia (AML)5, resistance to conventional therapies6–8 and dismal outcomes9. Consistent with the tumor-suppressive role of TP53, patients harbor both mono- and biallelic mutations10. However, the biological and clinical implications of TP53 allelic state have not been fully investigated in MDS or any other cancer type. We analyzed 3,324 patients with MDS for TP53 mutations and allelic imbalances and delineated two subsets of patients with distinct phenotypes and outcomes. One-third of TP53-mutated patients had monoallelic mutations whereas two-thirds had multiple hits (multi-hit) consistent with biallelic targeting. Established associations with complex karyotype, few co-occurring mutations, high-risk presentation and poor outcomes were specific to multi-hit patients only. TP53 multi-hit state predicted risk of death and leukemic transformation independently of the Revised International Prognostic Scoring System (IPSS-R)11. Surprisingly, monoallelic patients did not differ from TP53 wild-type patients in outcomes and response to therapy. This study shows that consideration of TP53 allelic state is critical for diagnostic and prognostic precision in MDS as well as in future correlative studies of treatment response. Clinical sequencing across a large prospective cohort of patients with myelodysplasic syndrome uncovers distinct associations between the mono- and biallelic states of TP53 and clinical presentation
301 citations
TL;DR: Differences in survival depending on resection status, especially in RPA classes IV and V, support a causal influence of resection on survival.
Abstract: The benefit of cytoreductive surgery for glioblastoma multiforme (GBM) is unclear, and selection bias in past series has been observed. The 5-aminolevulinic acid (ALA) study investigated the influence of fluorescence-guided resections on outcome and generated an extensive database of GBM patients with optimized resections. We evaluated whether the Radiation Therapy Oncology Group recursive partitioning analysis (RTOG-RPA) would predict survival of these patients and whether there was any benefit from extensive resections depending on RPA class. A total of 243 per-protocol patients with newly diagnosed GBM were operated on with or without ALA and treated by radiotherapy. Postoperative MRI was obtained in all patients. Patients were allocated into RTOG-RPA classes III-V based on age, KPS, neurological condition, and mental status (as derived from the NIH Stroke Scale). Median overall survival among RPA classes III, IV, and V was 17.8, 14.7, and 10.7 months, respectively, with 2-year survival rates of 26%, 12%, and 7% (p = 0.0007). Stratified for degree of resection, survival of patients with complete resections was clearly longer in RPA classes IV and V (17.7 months vs. 12.9 months, p = 0.0015, and 13.7 months vs. 10.4 months, p = 0.0398; 2-year rates: 21.0% vs. 4.4% and 11.1% vs. 2.6%, respectively), but was not in the small subgroup of RPA class III patients (19.3 vs. 16.3 months, p = 0.14). Survival of patients from the ALA study is correctly predicted by the RTOG-RPA classes. Differences in survival depending on resection status, especially in RPA classes IV and V, support a causal influence of resection on survival.
301 citations
Northern Arizona University1, National Institutes of Health2, University of Minnesota3, University of California, Davis4, Woods Hole Oceanographic Institution5, Massachusetts Institute of Technology6, University of Copenhagen7, University of Trento8, Chinese Academy of Sciences9, University of California, San Francisco10, University of Pennsylvania11, Pacific Northwest National Laboratory12, North Carolina State University13, University of Montana14, Institute for Systems Biology15, Dalhousie University16, University of British Columbia17, Statens Serum Institut18, Anschutz Medical Campus19, University of Washington20, University of California, San Diego21, Michigan State University22, Stanford University23, Broad Institute24, Harvard University25, Australian National University26, University of Düsseldorf27, University of New South Wales28, Sookmyung Women's University29, San Diego State University30, Howard Hughes Medical Institute31, Cornell University32, Max Planck Society33, Colorado State University34, Google35, Syracuse University36, Webster University37, United States Department of Agriculture38, University of Arkansas for Medical Sciences39, Colorado School of Mines40, University of Southern Mississippi41, National Oceanic and Atmospheric Administration42, University of California, Merced43, Wageningen University and Research Centre44, University of Arizona45, Environment Agency46, University of Florida47, Merck & Co.48
TL;DR: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Abstract: In the version of this article initially published, some reference citations were incorrect. The three references to Jupyter Notebooks should have cited Kluyver et al. instead of Gonzalez et al. The reference to Qiita should have cited Gonzalez et al. instead of Schloss et al. The reference to mothur should have cited Schloss et al. instead of McMurdie & Holmes. The reference to phyloseq should have cited McMurdie & Holmes instead of Huber et al. The reference to Bioconductor should have cited Huber et al. instead of Franzosa et al. And the reference to the biobakery suite should have cited Franzosa et al. instead of Kluyver et al. The errors have been corrected in the HTML and PDF versions of the article.
301 citations
Ruhr University Bochum1, Bar-Ilan University2, Martin Luther University of Halle-Wittenberg3, Leibniz Institute for Neurobiology4, University of Regensburg5, University of Freiburg6, University of Düsseldorf7, Max Delbrück Center for Molecular Medicine8, University of Erlangen-Nuremberg9, University of California, Los Angeles10, Leipzig University11
TL;DR: It is suggested that PA can serve as a potent immunomodulatory supplement to MS drugs and as an add-on to MS immunotherapy.
301 citations
Authors
Showing all 25575 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Karl J. Friston | 217 | 1267 | 217169 |
| Roderick T. Bronson | 169 | 679 | 107702 |
| Stanley B. Prusiner | 168 | 745 | 97528 |
| Ralph A. DeFronzo | 160 | 759 | 132993 |
| Monique M.B. Breteler | 159 | 546 | 93762 |
| Thomas Meitinger | 155 | 716 | 108491 |
| Karl Zilles | 138 | 692 | 72733 |
| Ruben C. Gur | 136 | 741 | 61312 |
| Alexis Brice | 135 | 870 | 83466 |
| Michael Schmitt | 134 | 2007 | 114667 |
| Michael Weller | 134 | 1105 | 91874 |
| Helmut Sies | 133 | 670 | 78319 |
| Peter T. Fox | 131 | 622 | 83369 |
| Yuri S. Kivshar | 126 | 1845 | 79415 |
| Markus M. Nöthen | 125 | 943 | 83156 |